title: Predicting in-hospital mortality in acute myocardial infarction: impact of thrombolytic therapy on APACHE II performance.
abstract: OBJECTIVE
  To study the usefulness of the Second Acute Physiology and Chronic Health Evaluation (APACHE II) scoring system for prognostication of in-hospital mortality in patients with acute myocardial infarction treated with thrombolysis.
  
  
  METHODS
  A prospective validation study was conducted at a medical intensive care unit at a university hospital. Over a 3-year period, 1714 patients with acute myocardial infarction were studied (mean age 72+/-10 years). Thrombolytic therapy was the prescribed treatment for 316 patients and total hospital mortality was 16%.
  
  
  RESULTS
  The patients who received thrombolysis were younger, had higher blood pressure, lower heart and respiratory rates and higher Glasgow Coma Scale scores. Total in-hospital mortality was 9.5% in patients treated with thrombolysis and 17.1% in untreated patients (p < 0.01). Corresponding APACHE II predictions of mortality were 11.8 and 15.8% (p < 0.01). There was no significant difference between observed and predicted mortality. When a decision rule of 50% predicted risk of death was employed, sensitivity was 20% and specificity 99% in the thrombolytic group, while the corresponding figures in the nonthrombolytic group were 31% and 97%, respectively.
  
  
  CONCLUSIONS
  In-hospital mortality in groups of patients treated with or without thrombolysis for acute myocardial infarction could be predicted with the APACHE II scoring system. Prognostication in individual patients is not possible with the APACHE II system.
authors.affiliation: Department of Medicine, Söder Hospital, Stockholm, Sweden. ulf.ludwigs@divmed.ks.se
authors.forename: U
authors.initials: U
authors.lastname: Ludwigs
authors.forename: M
authors.initials: M
authors.lastname: Csatlos
authors.forename: J
authors.initials: J
authors.lastname: Hulting
mesh_terms: D018806:APACHE; D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006334:Heart Function Tests; D006439:Hemodynamics / Q000502:physiology; D017052:Hospital Mortality; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012720:Severity of Illness Index; D013300:Streptokinase / Q000008:administration & dosage*; D015996:Survival Rate; D015912:Thrombolytic Therapy / Q000379:methods* / Q000401:mortality*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase